Available in one strength of 50/500 mcg; it is licensed for adults aged 18 years and over.1
Aerivio Spiromax® is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:
Chronic Obstructive Pulmonary Disease (COPD)
Aerivio Spiromax® is indicated for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.1
The launch of Aerivio Spiromax® extends the treatments available from the Spiromax® inhaler, following the launch of DuoResp Spiromax® (budesonide/formoterol) in 2014.
Aerivio Spiromax® brings together the effective combination of salmeterol/fluticasone in a device that’s ready to use in one flip of the cover
Evidence suggests that inhalers which are easier for healthcare professionals to train, and for patients to use, can help to ensure correct inhaler technique and reduce non-adherence.2
In a qualitative study on patient and healthcare professional device preferences, the Spiromax® device was preferred by patients and healthcare professionals.*
Poor inhaler technique can lead to poor control of asthma and COPD. This may result in reduced lung deposition of inhaled medicines,4 and increase symptoms and exacerbations.5,6 These factors can also contribute to increased appointments and emergency hospital admissions.
The Spiromax® device has shown consistent dose delivery in real-word conditions**7 and provides dose confirmation to patients through the lactose taste and precise dose indicator. It requires no co-ordination of actuation or inhalation.7,8
In addition to the healthcare professional and patient benefits, Aerivio Spiromax® also provides cost-savings vs. Seretide® (salmeterol/fluticasone) Accuhaler® 50/500 mcg.9
*Patients currently used Turbohaler® or Accuhaler®, all healthcare professionals had experience in the regular treatment of asthma and COPD patients.
**Only DuoResp Spiromax® (budesonide/formoterol) studied
2031 GA Haarlem
Marketing Authorisation number(s)
1. Aerivio Spiromax® Summary of Product Characteristics
2. Price D et al. Resp Med 2013; 107:37-46
3. Plusa T, Bijos P. Int. Rev. Allergol Clin Immunol Family Med 2015; 21: 21-4
4. Giraud V, Roche N. Eur Resp J 2002; 19:246-251
5. Melani AS et al. Resp Med 2011; 105:930-938
6. Kemp L et al. Clinicoecon Outcomes Res 2010; 2:75-85
7. Canonica G et al. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2015; 28(5): 309-19.
8. Chrystyn H et al. Int J Pharm, 2015; 491: 268-76.
9. MIMS. Available at: http://www.mims.co.uk/drugs/respiratory-system/asthma-copd/seretideaccuhaler. Last accessed: February 2017.
To access this section of the Teva UK Limited website you need to be a member of the healthcare profession
because the materials included in this area of our website are specifically prepared for that audience
To understand why that is - please visit: Working in a regulated environment
Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.